Advertisement

Pretransplant Considerations in Patients with Obstructive Lung Disease: COPD, Lymphangioleiomyomatosis, Cystic Fibrosis, and Non-CF Bronchiectasis

  • Shahnaz Ajani
  • Robert M. Kotloff
Chapter

Abstract

Pulmonary diseases characterized by progressive and irreversible airflow obstruction include chronic obstructive pulmonary disease (COPD), lymphangioleiomyomatosis (LAM), cystic fibrosis (CF), and non-CF bronchiectasis. Despite advances in treatment of these diseases, all have the potential to progress to a far-advanced and life-threatening stage, prompting consideration of lung transplantation as a therapeutic option. Although considerable experience has been accrued in transplanting these patient populations, questions remain about the appropriate time to list patients, the true survival benefits of transplantation, and in the case of COPD and LAM, the best procedure to perform. This chapter will explore the available literature with the goal of offering an evidence- and/or consensus-based assessment of issues related to the pretransplant evaluation and management of patients with obstructive lung disorders.

Keywords

Chronic obstructive pulmonary disease Lymphangioleiomyomatosis Cystic fibrosis Bronchiectasis Lung transplantation Lung allocation score 

References

  1. 1.
    Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart And Lung Transplantation: thirty-third official adult lung and heart-lung transplantation report—2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1170–84.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Valapour M, Skeans MA, Smith JM, et al. Lung. Am J Transplant. 2016;16(Suppl 2):141–68.PubMedCrossRefGoogle Scholar
  3. 3.
    Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Budweiser S, Jorres RA, Riedl T, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest. 2007;131:1650–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Esteban C, Quintana JM, Aburto M, et al. The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. Respir Med. 2011;105:1662–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the Aspire Registry. Eur Respir J. 2013;41:1292–301.PubMedCrossRefGoogle Scholar
  8. 8.
    Yang H, Xiang P, Zhang E, et al. Is hypercapnia associated with poor prognosis in chronic obstructive pulmonary disease? A long-term follow-up cohort study. BMJ Open. 2015;5:e008909.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Golpe R, Perez-De-Llano LA, Mendez-Marote L, Veres-Racamonde A. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6-minute walk test in COPD patients. Respir Care. 2013;58:1329–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Takigawa N, Tada A, Soda R, et al. Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. Respir Med. 2007;101:561–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med. 1969;280:397–404.PubMedCrossRefGoogle Scholar
  12. 12.
    Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31:373–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Failure. 2009;11:1182–8.CrossRefGoogle Scholar
  14. 14.
    Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7:e43892.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Marti S, Munoz X, Rios J, Morell F, Ferrer J. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J. 2006;27:689–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. Respir Med. 2008;102:512–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and Bode index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103:692–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the Bode index predicts mortality in severe emphysema. Am J Respir Crit Care Med. 2008;178:491–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351:24–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet. 2008;371:744–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Lahzami S, Bridevaux PO, Soccal PM, et al. Survival impact of lung transplantation for COPD. Eur Respir J. 2010;36:74–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the pulmonary transplantation council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Chamogeorgakis T, Mason DP, Murthy SC, et al. Impact of nutritional state on lung transplant outcomes. J Heart Lung Transplant. 2013;32:693–700.PubMedCrossRefGoogle Scholar
  25. 25.
    Baldwin MR, Arcasoy SM, Shah A, et al. Hypoalbuminemia and early mortality after lung transplantation: a cohort study. Am J Transplant. 2012;12:1256–67.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Lederer DJ, Wilt JS, D’ovidio F, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med. 2009;180:887–95.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Vaquero-Barrios JM, Arenas-De Larriva MS, Redel-Montero J, et al. Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant. Transplant Proc. 2010;42:3020–2.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183:885–90.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Jastrzebski D, Lutogniewska W, Ochman M, et al. Osteoporosis in patients referred for lung transplantation. Eur J Med Res. 2010;15(Suppl 2):68–71.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Singer JP, Diamond JM, Gries CJ, et al. Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation. Am J Respir Crit Care Med. 2015;192:1325–34.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Meyers BF, Yusen RD, Guthrie TJ, et al. Outcome of bilateral lung volume reduction in patients with emphysema potentially eligible for lung transplantation. J Thorac Cardiovasc Surg. 2001;122:10–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Senbaklavaci O, Wisser W, Ozpeker C, et al. Successful lung volume reduction surgery brings patients into better condition for later lung transplantation. Eur J Cardiothorac Surg. 2002;22:363–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Burns KE, Keenan RJ, Grgurich WF, Manzetti JD, Zenati MA. Outcomes of lung volume reduction surgery followed by lung transplantation: a matched cohort study. Ann Thorac Surg. 2002;73:1587–93.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Bavaria JE, Pochettino A, Kotloff RM, et al. Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1998;115:9–17.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Nathan SD, Edwards LB, Barnett SD, Ahmad S, Burton NA. Outcomes of COPD lung transplant recipients after lung volume reduction surgery. Chest. 2004;126:1569–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Shigemura N, Gilbert S, Bhama JK, et al. Lung transplantation after lung volume reduction surgery. Transplantation. 2013;96:421–5.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Backhus L, Sargent J, Cheng A, Zeliadt S, Wood D, Mulligan M. Outcomes in lung transplantation after previous lung volume reduction surgery in a contemporary cohort. J Thorac Cardiovasc Surg. 2014;147:1678–83.E1.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points. J Heart Lung Transplant. 2001;20:935–41.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313:936–48.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Gaissert HA, Trulock EP, Cooper JD, Sundaresan RS, Patterson GA. Comparison of early functional results after volume reduction or lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1996;111:296–306.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Pochettino A, Kotloff RM, Rosengard BR, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease: intermediate-term results. Ann Thorac Surg. 2000;70:1813–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Sundaresan SR, Shiraishi Y, Trulock EP, et al. Single or bilateral lung transplantation for emphysema? J Thorac Cardiovasc Surg. 1996;112:1485–95.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Bossenbroek L, Ten Hacken NH, Van Der Bij W, Verschuuren EA, Koeter GH, De Greef MH. Cross-sectional assessment of daily physical activity in chronic obstructive pulmonary disease lung transplant patients. J Heart Lung Transplant. 2009;28:149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Gerbase MW, Spiliopoulos A, Rochat T, Archinard M, Nicod LP. Health-related quality of life following single or bilateral lung transplantation: a 7-year comparison to functional outcome. Chest. 2005;128:1371–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Levy RD, Ernst P, Levine SM, et al. Exercise performance after lung transplantation. J Heart Lung Transplant. 1993;12:27–33.PubMedGoogle Scholar
  47. 47.
    Williams TJ, Patterson GA, Mcclean PA, Zamel N, Maurer J. Maximal exercise testing in single and double lung transplant recipients. Am Rev Respir Dis. 1992;145:101–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Dickson RP, Davis RD, Rea JB, Palmer SM. High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant. 2006;25:1297–301.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Espinosa D, Baamonde C, Illana J, et al. Lung Cancer in patients with lung transplants. Transplant Proc. 2012;44:2118–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Grewal AS, Padera RF, Boukedes S, et al. Prevalence and outcome of lung cancer in lung transplant recipients. Respir Med. 2015;109:427–33.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Raviv Y, Shitrit D, Amital A, et al. Lung cancer in lung transplant recipients: experience of a tertiary hospital and literature review. Lung Cancer (Amsterdam, Netherlands). 2011;74:280–3.CrossRefGoogle Scholar
  52. 52.
    Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol. 2008;3:1404–9.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Weill D, Torres F, Hodges TN, Olmos JJ, Zamora MR. Acute native lung hyperinflation is not associated with poor outcomes after single lung transplant for emphysema. J Heart Lung Transplant. 1999;18:1080–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Reece TB, Mitchell JD, Zamora MR, et al. Native lung volume reduction surgery relieves functional graft compression after single-lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 2008;135:931–7.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Anderson MB, Kriett JM, Kapelanski DP, Perricone A, Smith CM, Jamieson SW. Volume reduction surgery in the native lung after single lung transplantation for emphysema. J Heart Lung Transplant. 1997;16:752–7.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Venuta F, De Giacomo T, Rendina EA, et al. Thoracoscopic volume reduction of the native lung after single lung transplantation for emphysema. Am J Respir Crit Care Med. 1997;156:292–3.CrossRefGoogle Scholar
  57. 57.
    Crespo MM, Johnson BA, Mccurry KR, Landreneau RJ, Sciurba FC. Use of endobronchial valves for native lung hyperinflation associated with respiratory failure in a single-lung transplant recipient for emphysema. Chest. 2007;131:214–6.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Pato O, Rama P, Allegue M, Fernandez R, Gonzalez D, Borro JM. Bronchoscopic lung volume reduction in a single-lung transplant recipient with natal lung hyperinflation: a case report. Transplant Proc. 2010;42:1979–81.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Mccurry KR, Shearon TH, Edwards LB, et al. Lung transplantation in the United States, 1998-2007. Am J Transplant. 2009;9:942–58.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Munson JC, Christie JD, Halpern SD. The societal impact of single versus bilateral lung transplantation for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184:1282–8.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Shah RJ, Kotloff RM. Lung transplantation for obstructive lung diseases. Semin Respir Crit Care Med. 2013;34:288–96.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Benden C, Rea F, Behr J, et al. Lung transplantation for Lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant. 2009;28:1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for Lymphangioleiomyomatosis. N Engl J Med. 1996;335:1275–80.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Pechet TT, Meyers BF, Guthrie TJ, et al. Lung transplantation for Lymphangioleiomyomatosis. J Heart Lung Transplant. 2004;23:301–8.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Reynaud-Gaubert M, Mornex JF, Mal H, et al. Lung transplantation for Lymphangioleiomyomatosis: the French experience. Transplantation. 2008;86:515–20.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Kpodonu J, Massad MG, Chaer RA, et al. The us experience with lung transplantation for pulmonary Lymphangioleiomyomatosis. J Heart Lung Transplant. 2005;24:1247–53.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Oprescu N, Mccormack FX, Byrnes S, Kinder BW. Clinical predictors of mortality and cause of death in Lymphangioleiomyomatosis: a population-based registry. Lung. 2013;191:35–42.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Machuca TN, Losso MJ, Camargo SM, et al. Lung transplantation for Lymphangioleiomyomatosis: single-center Brazilian experience with no Chylothorax. Transplant Proc. 2011;43:236–8.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in De novo lung transplantation with Sirolimus-based immunosuppression. J Heart Lung Transplant. 2004;23:632–8.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of Sirolimus immediately after lung transplantation. Transplantation. 2003;75:1437–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of Lymphangioleiomyomatosis: a phase ii study. Eur Respir J. 2015;46:783–94.PubMedCrossRefGoogle Scholar
  72. 72.
    El-Chemaly S, Goldberg HJ, Glanville AR. Should mammalian target of rapamycin inhibitors be stopped in women with Lymphangioleiomyomatosis awaiting lung transplantation? Expert Rev Respir Med. 2014;8:657–60.PubMedCrossRefGoogle Scholar
  73. 73.
    Mackenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med. 2014;161:233–41.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326:1187–91.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Doershuk CF, Stern RC. Timing of referral for lung transplantation for cystic fibrosis: overemphasis on Fev1 may adversely affect overall survival. Chest. 1999;115:782–7.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest. 1998;113:1230–4.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011;342:D1008.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004;126:412–9.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Martin C, Chapron J, Hubert D, et al. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med. 2013;107:1881–7.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Vizza CD, Yusen RD, Lynch JP, Fedele F, Alexander Patterson G, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2000;162:819–25.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005;171(9):1053.PubMedCrossRefGoogle Scholar
  83. 83.
    Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken M. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002;166:1550–5.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Salsgiver EL, Fink AK, Knapp EA, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149:390–400.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of Panresistant Bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997;155:1699–704.PubMedCrossRefGoogle Scholar
  86. 86.
    Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral Centre. J Hosp Infect. 2004;56:277–82.PubMedCrossRefGoogle Scholar
  87. 87.
    Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring Panresistant Bacteria other than Burkholderia Cepacia, compared with patients harboring sensitive Bacteria. J Heart Lung Transplant. 2007;26(8):834.PubMedCrossRefGoogle Scholar
  88. 88.
    Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007;42:525–32.PubMedCrossRefGoogle Scholar
  89. 89.
    Courtney JM, Dunbar KE, Mcdowell A, et al. Clinical outcome of Burkholderia Cepacia complex infection in cystic fibrosis adults. J Cyst Fibros. 2004;3:93–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Fauroux B, Hart N, Belfar S, et al. Burkholderia Cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol. 2004;42:5537–41.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Ledson MJ, Walshaw MJ. Burkholderia infection and survival in Cf. Thorax. 2005;60:439.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Zlosnik JE, Zhou G, Brant R, et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years’ experience. Ann Am Thorac Soc. 2015;12:70–8.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Aris RM, Routh JC, Lipuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia Cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med. 2001;164:2102–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia Cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia Cepacia complex. Am J Transplant. 2008;8:1025–30.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Murray S, Charbeneau J, Marshall BC, Lipuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.PubMedCrossRefGoogle Scholar
  97. 97.
    Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant. 1997;16:524–31.PubMedGoogle Scholar
  98. 98.
    Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114:1321–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis. 2012;14:452–60.PubMedCrossRefGoogle Scholar
  100. 100.
    Lobo LJ, Chang LC, Esther CR Jr, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with pre-operative mycobacterium abscessus respiratory infections. Clin Transpl. 2013;27:523–9.CrossRefGoogle Scholar
  101. 101.
    Aaron SD, Stephenson AL, Cameron DW, Whitmore GA. A statistical model to predict one-year risk of death in patients with cystic fibrosis. J Clin Epidemiol. 2015;68:1336–45.PubMedCrossRefGoogle Scholar
  102. 102.
    Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33:311–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Hayes D Jr, Patel AV, Black SM, et al. Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. J Thorac Cardiovasc Surg. 2015;150:707–13.PubMedCrossRefGoogle Scholar
  104. 104.
    Lewis C, Blackman SM, Nelson A, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191:194–200.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Hofer M, Schmid C, Benden C, et al. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibrosis. 2012;11:131–6.CrossRefGoogle Scholar
  106. 106.
    Stephenson AL, Sykes J, Berthiaume Y, et al. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Heart Lung Transplant. 2015;34:1139–45.PubMedCrossRefGoogle Scholar
  107. 107.
    Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest. 1996;109:1176–83.PubMedCrossRefGoogle Scholar
  108. 108.
    Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med. 2004;169:77–82.PubMedCrossRefGoogle Scholar
  109. 109.
    Aris RM, Lester GE, Renner JB, et al. Efficacy of Pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000;162:941–6.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Leung MK, Rachakonda L, Weill D, Hwang PH. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol. 2008;22:192–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Grannas G, Neipp M, Hoeper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation. 2008;85:524–31.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Nash EF, Volling C, Gutierrez CA, et al. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis. Clin Transpl. 2012;26:34–41.CrossRefGoogle Scholar
  113. 113.
    Klima LD, Kowdley KV, Lewis SL, Wood DE, Aitken ML. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. J Heart Lung Transplant. 1997;16:934–8.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Beirne PA, Banner NR, Khaghani A, Hodson ME, Yacoub MH. Lung transplantation for non-cystic fibrosis bronchiectasis: analysis of a 13-year experience. J Heart Lung Transplant. 2005;24:1530–5.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Nathan JA, Sharples LD, Exley AR, Sivasothy P, Wallwork J. The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency. J Heart Lung Transplant. 2005;24:1517–21.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council f the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–55.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Hayes D Jr, Kopp BT, Tobias JD, et al. Survival in patients with advanced non-cystic fibrosis bronchiectasis versus cystic fibrosis on the waitlist for lung transplantation. Lung. 2015;193:933–8.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  1. 1.Division of Pulmonary, Allergy, Critical Care, and Sleep MedicineEmory University Hospital, Emory University School of Medicine, Emory Transplant CenterAtlantaUSA
  2. 2.Department of Pulmonary MedicineCleveland ClinicClevelandUSA

Personalised recommendations